Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - Εμβόλια γρίπης - Προφύλαξη από τη γρίπη που προκαλείται από τον ιό a (h1n1v) 2009. Το focetria πρέπει να χρησιμοποιείται σύμφωνα με τις επίσημες οδηγίες.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

viatris healthcare limited. (0000012172) damastown industrial park, mulhuddart, dublin 15, d15 xd71 - a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/2570/2019, ivr-215); a/cambodia/e0826360/2020 (h3n2)-like strain (a/tasmania/503/2020, ivr-221); b/washington/02/2019-like strain (b/washington/02/2019, wild type) [victoria lineage]; b/phuket/3073/2013 – like strain (b/phuket/3073/2013, wild type) [yamagata lineage] - suspension for injection in pre-filled syringe - 15mcg/dose - a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/2570/2019, ivr-215) (8000004843) 15ug; a/cambodia/e0826360/2020 (h3n2)-like strain (a/tasmania/503/2020, ivr-221) (8000004848) 15ug; b/washington/02/2019-like strain (b/washington/02/2019, wild type) [victoria lineage] (8000004849) 15ug; b/phuket/3073/2013 – like strain (b/phuket/3073/2013, wild type) [yamagata lineage] (8000004705) 15ug - influenza, purified antigen

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

viatris healthcare limited, ireland damastown industrial park, - dublin - a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022, ivr-238); a/cambodia/e0826360/2020 (h3n2) - like strain a/cambodia/e0826360/2020, ivr-224); b/austria/1359417/2021 - like strain b/austria/1359417/2021, bvr-26); b/phuket/3073/2013-like strain (b/yamagata/16/88 lineage) (b/phuket/3073/2013, wild type) - inj.su.pfs (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - (15+15+15+15)mcg/0.5ml pf.syr. (1 δόση) - a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022, ivr-238) 15mcg; a/cambodia/e0826360/2020 (h3n2) - like strain a/cambodia/e0826360/2020, ivr-224) 15mcg; b/austria/1359417/2021 - like strain b/austria/1359417/2021, bvr-26) 15mcg; b/phuket/3073/2013-like strain (b/yamagata/16/88 lineage) (b/phuket/3073/2013, wild type) 15mcg - influenza, purified antigen

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - Εμβόλια - active immunisation against h5 subtype of influenza a virus.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - Εμβόλια - Ο hexyon (dtap-ipv-hb-hib) ενδείκνυται για αρχικό και αναμνηστικό εμβολιασμό των βρεφών και των νηπίων από έξι εβδομάδες της ηλικίας κατά της διφθερίτιδας, τετάνου, κοκκύτη, ηπατίτιδας Β, πολιομυελίτιδας και επεμβατική ασθένειες που προκαλούνται από Αιμόφιλο ινφλουέντζας τύπου b (hib). Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - Γρίπη, Ανθρώπινα - Εμβόλια - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - diphtheria toxoid; poliomyelitis virus type 3; tetanus toxoid; pertussis toxoid(pt); filamentous haemagglutinin (fha); poliomyelitis virus type 2; poliomyelitis virus type 1; haemophilus infl. type b polys.conj.t.toxoid - powder & suspension for suspension for injection - diphtheria toxoid (8000000804) 0iu; poliomyelitis virus type 3 (8000000485) 32du; tetanus toxoid (8000040440) 0iu; pertussis toxoid(pt) (8000001811) 25mcg; filamentous haemagglutinin (fha) (8000001813) 25mcg; poliomyelitis virus type 2 (8000000484) 8du; poliomyelitis virus type 1 (8000000483) 40du; haemophilus infl. type b polys.conj.t.toxoid (8000001810) 10mcg - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - haemagglutinin of equine influenza virus (inactivated) a/equine/1 newmarket 77; haemagglutinin of equine influenza virus (inactivated) a/equine/2 borlange 91; haemagglutinin of equine influenza virus (inactivated) a/equine/1 kentucky 1/98 - suspension for injection - haemagglutinin of equine influenza virus (inactivated) a/equine/1 newmarket 77 (8900000222) 10mcg; haemagglutinin of equine influenza virus (inactivated) a/equine/2 borlange 91 (8900000223) 20mcg; haemagglutinin of equine influenza virus (inactivated) a/equine/1 kentucky 1/98 (8900000224) 1.4mcg - equine influenza virus

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - haemagglutinin of equine influenza virus (inactivated) a/equine/1 newmarket 77; haemagglutinin of equine influenza virus (inactivated) a/equine/2 borlange 91; haemagglutinin of equine influenza virus (inactivated) a/equine/1 kentucky 1/98; immunopurified tetanus toxoid - suspension for injection - haemagglutinin of equine influenza virus (inactivated) a/equine/1 newmarket 77 (8900000222) 10mcg; haemagglutinin of equine influenza virus (inactivated) a/equine/2 borlange 91 (8900000223) 20mcg; haemagglutinin of equine influenza virus (inactivated) a/equine/1 kentucky 1/98 (8900000224) 1.4mcg; immunopurified tetanus toxoid (8900000226) 100lfu - equine influenza virus + clostridium

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

sanofi pasteur europe, france 14 espace henry vallee, 69007 lyon +33 437 28 40 00 - purified tetanus toxoid; purified diphteria toxoid; purified pertussis toxoid (pt xd); filamentous haemagglutinin (fha); inactivated poliovirus vacc type i; inactivated poliovirus vacc type ii; inactivated poliovirus vacc type iii; haemophilus type b polysac. conjugated to tetanus protein - inj.susp (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ); pd.inj.sus (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ) - 0,5ml (1dose) - purified tetanus toxoid 40iu; purified diphteria toxoid 20iu; purified pertussis toxoid (pt xd) 25mcg; filamentous haemagglutinin (fha) 25mcg; inactivated poliovirus vacc type i 29u; inactivated poliovirus vacc type ii 7u; inactivated poliovirus vacc type iii 26u; haemophilus type b polysac. conjugated to tetanus protein 10mcg - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus